Acarix ( ) - 株価, ニュースと分析OM:ACARIX

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

ACARIX 株式概要

医療機器メーカーであるAcarix AB (publish)は、AIベースの迅速な冠動脈疾患（CAD）除外のためのソリューションを開発している。

ACARIX ファンダメンタル分析
スノーフレーク・スコア
評価	0/6
将来の成長	2/6
過去の実績	0/6
財務の健全性	6/6
配当金	0/6

報酬

収益は年間76.88%増加すると予測されています

リスク分析

収益が 100 万ドル未満 ( SEK6M )

過去1年間で株主の希薄化は大幅に進んだ

現在は利益が出ておらず、今後3年間で利益が出る見込みはない

意味のある時価総額がありません ( SEK316M )

+1 さらなるリスク

Acarix AB (publ) 競合他社

Boule Diagnostics

OM:BOUL

SEK 394.2m

BrainCool

OM:BRAIN

SEK 600.5m

Q-linea

OM:QLINEA

SEK 465.6m

Ortoma

OM:ORT B

SEK 321.9m

価格と性能

の歴代最高値、変動、値下がりまとめAcarix
過去の株価
現在の株価	SEK 0.49
52週高値	SEK 0.59
52週安値	SEK 0.17
ベータ	1.4
11ヶ月の変化	66.10%
3ヶ月変化	97.98%
1年変化	-15.52%
33年間の変化	-64.75%
5年間の変化	-89.35%
IPOからの変化	-96.99%

Will Acarix (STO:ACARIX) Spend Its Cash Wisely?

Jun 13

Recent updates

株主還元

	ACARIX	SE Medical Equipment	SE 市場
7D	23.4%	1.9%	0.6%
1Y	-15.5%	1.9%	15.9%

業界別リターン: ACARIX過去 1 年間で-6.4 % の収益を上げたSwedish Medical Equipment業界を下回りました。

リターン対市場: ACARIXは、過去 1 年間で13 % のリターンを上げたSwedish市場を下回りました。

価格変動

Is ACARIX's price volatile compared to industry and market?
ACARIX volatility
ACARIX Average Weekly Movement	9.6%
Medical Equipment Industry Average Movement	7.6%
Market Average Movement	5.8%
10% most volatile stocks in SE Market	12.2%
10% least volatile stocks in SE Market	3.4%

安定した株価: ACARIXの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: ACARIXの weekly volatility ( 9% ) は過去 1 年間安定していますが、依然としてSwedishの株式の 75% よりも高くなっています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
2009	14	Aamir Mahmood	www.acarix.com

医療機器メーカーであるAcarix AB (publish)は、AIを用いた迅速な冠動脈疾患（CAD）除外のためのソリューションを開発している。同社は、高感度音響と高度な計算処理を用いて患者の冠動脈血流を解析するポイントオブケア診断補助装置CADScor Systemを提供している。北欧諸国、英国、ドイツ、スイス、オーストリア、モーリシャス、米国で製品を販売している。同社は2009年に設立され、スウェーデンのマルメに本社を置いている。

Acarix AB (publ) 基礎のまとめ

Acarix の収益と売上を時価総額と比較するとどうか。
ACARIX 基礎統計学
時価総額	SEK 476.85m
収益（TTM）	-SEK 76.29m
売上高(TTM)	SEK 5.84m

81.7x

P/Sレシオ

-6.3x

PER（株価収益率

ACARIX は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
ACARIX 損益計算書（TTM）
収益	SEK 5.84m
売上原価	SEK 815.00k
売上総利益	SEK 5.02m
その他の費用	SEK 81.31m
収益	-SEK 76.29m

直近の収益報告

Mar 31, 2024

次回決算日

Aug 22, 2024

一株当たり利益（EPS）	-0.078
グロス・マージン	86.04%
純利益率	-1,306.56%
有利子負債／自己資本比率	0%

ACARIX の長期的なパフォーマンスは？

過去の実績と比較を見る

ACARIX 株式概要

報酬

リスク分析

Acarix AB (publ) 競合他社

OM:BOUL

SEK 394.2m

OM:BRAIN

SEK 600.5m

OM:QLINEA

SEK 465.6m

OM:ORT B

SEK 321.9m

価格と性能

最新ニュース

Acarix AB (publ) announced that it expects to receive SEK 21 million in funding

Will Acarix (STO:ACARIX) Spend Its Cash Wisely?

Acarix Announces Enrollment of First Patient in Us-Based Clinical Workflow Evaluation Study

Acarix AB (Publ) Appoints Jeff Thomas as the New Head of US Sales, Effective June 1, 2024

First quarter 2024 earnings released: kr0.019 loss per share (vs kr0.045 loss in 1Q 2023)

Acarix AB (publ) Approves Board Elections

Recent updates

Acarix AB (publ) announced that it expects to receive SEK 21 million in funding

Will Acarix (STO:ACARIX) Spend Its Cash Wisely?

Acarix Announces Enrollment of First Patient in Us-Based Clinical Workflow Evaluation Study

Acarix AB (Publ) Appoints Jeff Thomas as the New Head of US Sales, Effective June 1, 2024

First quarter 2024 earnings released: kr0.019 loss per share (vs kr0.045 loss in 1Q 2023)

Acarix AB (publ) Approves Board Elections

Acarix AB Announces Initiation of the First Us-Based Clinical Workflow Evaluation Study

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Full year 2023 earnings released: kr0.16 loss per share (vs kr0.31 loss in FY 2022)

Acarix Appoints New Members to the Advisory Board

New major risk - Share price stability

Acarix AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 33.667038 million.

Acarix AB (publ) Announces CEO Changes

Chief Operations Officer recently bought kr157k worth of stock

Acarix AB (publ) to Report Q3, 2024 Results on Nov 07, 2024

Acarix AB (publ) Advances the Utilization of Its CADScor System Within the Veterans Administration (Va) Healthcare Network

New major risk - Financial position

Third quarter 2023 earnings released: kr0.038 loss per share (vs kr0.084 loss in 3Q 2022)

Acarix AB (publ) has completed a Composite Units Offering in the amount of SEK 54.344161 million.

Price target increased by 18% to kr0.90

Second quarter 2023 earnings released: kr0.051 loss per share (vs kr0.073 loss in 2Q 2022)

Acarix AB (Publ) Appoints Dr. Deepak R. Talreja Md as New Medical Advisor

Acarix AB Elects Mikael Thorén as Director

Full year 2022 earnings released: kr0.31 loss per share (vs kr0.37 loss in FY 2021)

Full year 2022 earnings released: kr0.31 loss per share (vs kr0.37 loss in FY 2021)

Acarix AB (publ) to Report Fiscal Year 2022 Final Results on Apr 20, 2023

Acarix AB (publ) to Report Q4, 2023 Results on Feb 15, 2024

Acarix AB (publ) to Report Q4, 2022 Results on Feb 16, 2023

Acarix AB (publ) to Report Q3, 2022 Results on Nov 16, 2022

Acarix AB (publ) Announces Patient Enrollment Completed in the Filter-Scad Randomized Controlled Multi-Center Trial

Second quarter 2022 earnings released: kr0.073 loss per share (vs kr0.093 loss in 2Q 2021)

Acarix AB (publ) to Report Q2, 2022 Results on Aug 25, 2022

Here's Why We're Watching Acarix's (STO:ACARIX) Cash Burn Situation

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to kr2.60

No independent directors

Acarix AB (publ), Annual General Meeting, May 11, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Acarix Submits Breakthrough Designation Request with Food and Drug Administration for Heart Failure Diagnosis

Acarix AB (Publ) Announces CE Approval and FDA Denovo of CADScor System

Third quarter 2021 earnings released: kr0.076 loss per share (vs kr0.11 loss in 3Q 2020)

We're Keeping An Eye On Acarix's (STO:ACARIX) Cash Burn Rate

Second quarter 2021 earnings released: kr0.093 loss per share (vs kr0.20 loss in 2Q 2020)

Will Acarix (STO:ACARIX) Spend Its Cash Wisely?

Director has left the company

Director has left the company

Director has left the company

Chairman of the Board Werner Braun has left the company

First quarter 2021 earnings released: kr0.083 loss per share (vs kr0.21 loss in 1Q 2020)

Full year 2020 earnings released: kr0.51 loss per share (vs kr1.83 loss in FY 2019)

Director recently bought kr890k worth of stock

Companies Like Acarix (STO:ACARIX) Are In A Position To Invest In Growth

New 90-day low: kr1.12

Acarix AB (publ) Announces Positive Preliminary Data from the Exploratory SEISMO Study

Acarix Receives US Market Approval for the CADScor System

New 90-day high: kr1.29

Acarix AB (Publ) Announces Positive Results from Acarix study presented at ISPOR

Third quarter 2020 earnings released: kr0.11 loss per share